Neuroprotection of Glibenclamide against Brain Injury after Cardiac Arrest via Modulation of NLRP3 Inflammasome.
RatIschaemia-reperfusionCerebral (MCAO/stroke)WistarMalen = 16 rats, 8 per groupIntraperitoneal injectionLoading dose 10 ug/kg, then maintenance doses of 1.6 ug/kgLoading dose 10 minutes after return of spontaneous circulation
Model: 8-minute asphyxial cardiac arrest with cardiopulmonary resuscitation, producing global ischaemic brain injury
Glibenclamide improved neurological deficit scores (median 51 versus 46, p less than 0.01) and quantitative EEG recovery (0.77 +/- 0.06 versus 0.63 +/- 0.04, p less than 0.001), with a trend to better 72-hour survival, and markedly reduced hippocampal NLRP3 and caspase-1 activation.
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.